OncoCyte (NYSE:OCX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of OncoCyte (NYSE:OCX – Get Rating) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

OncoCyte Stock Performance

Shares of OCX stock opened at $0.34 on Monday. The company’s 50 day moving average is $0.40. The firm has a market capitalization of $40.74 million, a P/E ratio of -0.53 and a beta of 1.70. OncoCyte has a 12 month low of $0.24 and a 12 month high of $1.68.

About OncoCyte

(Get Rating)

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services.